New Inversion Regs Won't Hinder $16.6B Johnson-Tyco Tie-Up
By Braden Campbell · April 21, 2016, 1:45 PM EDT
The newly unveiled anti-tax inversion regulations that thwarted Pfizer Inc.'s plan to combine with Irish drugmaker Allergan PLC earlier this month will not do the same for Johnson Controls Inc.'s $16.6...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login